• Facebook
  • Twitter
  • RSS
70°
Thursday August 28, 2014
View complete forecast
News-Sentinel.com Your Town. Your Voice.
Local Business Search
Stock Summary
Dow17067.15-54.86
Nasdaq4558.24-11.38
S&P 5001995.34-4.78
AEP53.125-0.025
Comcast54.49-0.07
GE26.04-0.09
ITT Exelis17.1750.025
LNC54.43-0.39
Navistar38.030.03
Raytheon95.72-0.44
SDI23.1901-0.2999
Verizon49.39-0.04

US employers posted fewer jobs, but hired more

Wednesday, September 11, 2013 - 12:01 am

WASHINGTON – U.S. employers advertised fewer jobs in July but hired more workers, a mixed sign that suggests only modest improvement in the job market.

The Labor Department says job openings fell 180,000 in July to 3.7 million. That's down from 3.9 million the previous month, which was revised lower. Overall hiring increased to 4.4 million, up from 4.3 million in June and 4.17 million a year ago. On Friday, the government said employers added 169,000 jobs in August and many fewer in the previous two months. The unemployment rate fell to 7.3 percent, but only because more people gave up looking for work.

US safety agency probes BMW 328i for brake problem

DETROIT – U.S. safety regulators are investigating brake problems in 90,000 late-model BMW cars. The National Highway Traffic Safety Administration says the probe covers the 328i from the 2013 model year. The government has received four complaints from drivers that it was difficult to brake the cars. Some reported increased stopping distances. The agency says that in three complaints, dealers found problems with a vacuum pump. No crashes or injuries have been reported. Investigators will determine if the problem is large enough to warrant a recall.

FDA: Roche drug works in early-stage breast cancer

WASHINGTON – The Food and Drug Administration has issued a positive review of a breast cancer drug from Roche that could soon become the first pharmaceutical option for treating the earliest stages of the disease.

In documents posted online, FDA scientists said women who received the drug Perjeta to treat early-stage breast cancer had significantly fewer tumors than women who received older drug combinations. While the results come from midstage trials of the drug, FDA scientists recommended accelerating approval of the drug. That step is reserved for groundbreaking drugs to treat life-threatening diseases.

Perjeta was first approved last summer to treat women with aggressive breast cancer that has already spread to other parts of the body. Roche's Genentech unit is now seeking approval to use the drug after diagnosis and before surgery to remove the tumor.

– From wire reports